1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? [Yahoo! Finance]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
While one analyst trimmed her price target on the stock in response, she's still extremely bullish on its prospects. In fact, she believes it could nearly triple before long. Might she be on to something here? Slight price target cut from a bull That analyst is Citigroup prognosticator Samantha Semenkow. In the wake of Editas' latest earnings release, she shaved $1 off her price target on the company to $15 per share. She maintained her buy recommendation, since that lower target was still roughly three times the stock's price at the time. Semenkow is staying the course despite Editas' disappointing first-quarter performance. The gene-editing company's revenue came in at $1.1 million in the first quarter, a precipitous drop from $9.9 million in the same period a year ago and far below the average pundit estimate of slightly less than $11 million. The story was similar on the bottom line; Editas saw its net loss balloon to almost $62 million ($0.76 per share) from the year-ago
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June [Yahoo! Finance]Yahoo! Finance
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in JuneGlobeNewswire
- Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]Yahoo! Finance
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire
EDIT
Earnings
- 5/8/24 - Miss
EDIT
Sec Filings
- 5/17/24 - Form 144
- 5/14/24 - Form 4
- 5/8/24 - Form 10-Q
- EDIT's page on the SEC website